Clinical Trials Logo

Pelvic Neoplasm clinical trials

View clinical trials related to Pelvic Neoplasm.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05258383 Not yet recruiting - Breast Cancer Clinical Trials

Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests

ELISA
Start date: May 15, 2023
Phase:
Study type: Observational

In image-guided radiotherapy (IGRT), the repeated and increasingly intensive use of on-board positioning imaging, using 2D or 3D Mega-Volt (MV) or kilo-Volt (kV) imaging devices (cone-beam or CBCT scanners), is leading the international medical community to question the potential impact of these additional doses delivered to the patient, especially in at-risk populations such as children and young adults. The doses delivered to the patient by positioning imaging are still relatively unknown, due to the lack of experimental means and software available in clinical routine to easily and accurately evaluate these doses. The main objective is to estimate by personalized Monte Carlo calculation the physical doses delivered to the patient's organs by the onboard imaging systems during their radiotherapy treatment. The obtained imaging doses will be compared according to different irradiation scenarios commonly used in clinical routine as well as according to the treated location.

NCT ID: NCT03168048 Not yet recruiting - Breast Cancer Clinical Trials

Oncologic Therapy Support Via Means of a Dedicated Mobile App

OPTIMISE-1
Start date: July 2017
Phase: N/A
Study type: Interventional

The present single-center prospective exploratory study, conducted at Heidelberg University Hospital, assesses the feasibility of introducing a concept for additional patient care based on a mobile application for patients undergoing radiotherapy. Patients presenting themselves for the irradiation of thoracic or pelvic tumors will be surveyed regarding general performance, treatment-related Quality of Life (QoL) and symptoms and their need to personally consult a physician on a treatment-daily basis by means of a mobile application. The primary endpoint of feasibility will be reached when 80% of the patients have successfully answered 80% of their respective questions scheduled for each treatment day. Furthermore, treatment-related patient satisfaction and diagnosis-related QoL is assessed by PSQ-18 and EORTC questionnaires at the end of radiotherapy and at the first follow-up.